ACTIBLE 150MG

About

Actible 150mg, containing Ibandronic Acid, is a potent bisphosphonate medication primarily used in the treatment and prevention of osteoporosis in postmenopausal women. It works by inhibiting osteoclast activity, which are the cells responsible for bone resorption, thereby reducing bone turnover and increasing bone mineral density. This action helps to strengthen bones, reduce the risk of vertebral and non-vertebral fractures, and improve overall bone health. Ibandronic acid is particularly valued for its convenient once-monthly oral dosing regimen, which can enhance patient adherence compared to daily or weekly bisphosphonates. It is crucial for patients to follow specific administration instructions to maximize absorption and minimize potential gastrointestinal side effects. Regular monitoring of bone density and calcium levels is recommended during treatment.

Uses

• Treatment of postmenopausal osteoporosis.
• Prevention of postmenopausal osteoporosis.
• Reduction of vertebral fracture risk.
• Increase in bone mineral density.

Directions For Use

Take one tablet once a month, on the same date each month, at least 60 minutes before the first food or drink (other than plain water) of the day. Swallow whole with a full glass of plain water while standing or sitting upright.

Benefits

• Increases bone mineral density.
• Reduces the risk of vertebral fractures.
• Convenient once-monthly dosing.
• Helps prevent bone loss.
• Supports long-term bone health.
• Well-established efficacy in osteoporosis.

Side Effects

• Heartburn
• Esophagitis
• Dyspepsia
• Abdominal pain
• Nausea
• Diarrhea
• Muscle pain
• Joint pain
• Headache
• Flu-like symptoms
• Dizziness
• Rare: Osteonecrosis of the jaw

Safety Measures

• Alcohol - Excessive alcohol intake can contribute to bone loss and may reduce the effectiveness of ibandronic acid. Moderate consumption is generally advised.
• Pregnancy - Ibandronic acid is contraindicated in pregnancy due to potential fetal harm. It should not be used by women who are pregnant or planning to conceive.
• Breastfeeding - It is unknown if ibandronic acid is excreted in human milk. Due to potential risks to the infant, breastfeeding is not recommended during treatment.
• Liver - No dose adjustment is typically required for patients with liver impairment, as ibandronic acid is not metabolized by the liver.
• Kidney - Ibandronic acid is not recommended for patients with severe renal impairment (creatinine clearance < 30 mL/min) due to increased exposure.
• Lung - No specific contraindications or dose adjustments are generally required for patients with lung conditions.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.